The London Life Sciences team advised Life Molecular on an out-licensing agreement with Lantheus for global therapeutic and diagnostic rights to Life Molecular’s RM2 product, which targets the gastrin-releasing peptide receptor (GRPR), including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2. The product has particular potential for addressing unmet medical needs in prostate and breast cancer treatment. Lantheus intends to begin a Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer patients in 2025. 68Ga-DOTA-RM2 will be used as a companion diagnostic. The agreement includes an upfront payment of $35 million and potential regulatory milestone payments plus royalties.
Life Molecular is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Life Molecular is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the private healthcare sector in southern Africa.
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years.
The Goodwin deal team consisted of Morag Peberdy and Lucy Sharples.
For more details, please see the press release.